131 related articles for article (PubMed ID: 1394221)
21. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
22. Neovasculature induced by vascular endothelial growth factor is fenestrated.
Roberts WG; Palade GE
Cancer Res; 1997 Feb; 57(4):765-72. PubMed ID: 9044858
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
[TBL] [Abstract][Full Text] [Related]
24. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
25. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
26. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
27. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
28. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
29. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
30. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues.
Halloran PF; Urmson J; Van der Meide PH; Autenried P
J Immunol; 1989 Jun; 142(12):4241-7. PubMed ID: 2498428
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.
Kirch ME; Hammerling U
J Immunol; 1981 Aug; 127(2):805-10. PubMed ID: 6788849
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
34. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
Durrant D; Corwin F; Simoni D; Zhao M; Rudek MA; Salloum FN; Kukreja RC; Fatouros PP; Lee RM
Cancer Chemother Pharmacol; 2009 Jan; 63(2):191-200. PubMed ID: 18365199
[TBL] [Abstract][Full Text] [Related]
35. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
36. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
37. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature.
Huang X; Molema G; King S; Watkins L; Edgington TS; Thorpe PE
Science; 1997 Jan; 275(5299):547-50. PubMed ID: 8999802
[TBL] [Abstract][Full Text] [Related]
38. Localization of neuroblastoma in vivo with tumor-specific antibodies.
Terman DS; Stewart I; Tavel A; Kirch D
Cancer Res; 1975 Jul; 35(7):1761-6. PubMed ID: 1093675
[TBL] [Abstract][Full Text] [Related]
39. Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model.
Burrows FJ; Overholser JP; Thorpe PE
Cell Biophys; 1994; 24-25():15-25. PubMed ID: 7736519
[TBL] [Abstract][Full Text] [Related]
40. Antibody-directed targeting of the vasculature of solid tumors.
Thorpe PE; Burrows FJ
Breast Cancer Res Treat; 1995; 36(2):237-51. PubMed ID: 8534871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
